DOI: https://dx.doi.org/10.18565/urology.2022.4.38-43
В.С. Петов, А.К. Базаркин, А.О. Морозов, М.С. Тараткин, Т.М. Ганжа, С.П. Данилов, Я.Н. Чернов, Д.В. Чиненов, А.В. Амосов, Д.В. Еникеев, Г.Е. Крупинов
1) Институт урологии и репродуктивного здоровья человека ФГАОУ ВО «Первый МГМУ им. И. М. Сеченова» Минздрава России (Сеченовский Университет) Москва, Россия; 2) Институт клинической медицины им. Н. В. Склифосовского ФГАОУ ВО «Первый МГМУ им. И. М. Сеченова» Минздрава России (Сеченовский Университет) Москва, Россия
1. Clinical recommendations. Prostate cancer. 2021. Available from: https://oncology-association.ru/wp-content/uploads/2021/02/rpzh.pdf. Russian (Клинические рекомендации. Рак предстательной железы. 2021; Available from: https://oncology-association.ru/wp-content/uploads/2021/02/rpzh.pdf). 2. De Santis M., Fanti S., Gillessen S., Grummet J., Henry A., Lam T., et al. Prostate Cancer EAU-EANM-ESTRO-ESUR-SIOG Guidelines on. 2019; 3. Drost F.-J.H., Osses D.F., Nieboer D., Steyerberg E.W., Bangma C.H., Roobol M.J., et al. Prostate M.R.I., with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019 Apr;4(4), Doi: 10.1002/14651858.CD012663.PUB2/ 4. Kasivisvanathan V., Rannikko A.S., Borghi M., Panebianco V., Mynderse L.A., Vaarala M.H., et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 5. Rouvière O., Puech P., Renard-Penna .R, Claudon M., Roy C., Mège-Lechevallier F., et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1), Doi: 10.1016/S1470-2045(18)30569-2. 6. Zhang K., Zhang Z., Liu M., Zhu G., Roobol M.J. Comparison of clinically significant prostate cancer detection by MRI cognitive biopsy and in-bore MRI-targeted biopsy for naïve biopsy patients. Transl Androl Urol 7. Elkhoury F.F., Felker E.R., Kwan L., Sisk A.E., Delfin M., Natarajan S., et al. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. JAMA Surg 8. Wegelin O., Exterkate L., van der Leest M., Kummer J.A., Vreuls W., de Bruin P.C., et al. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol. 2019;75(4):582–590. Doi: 10.1016/j.eururo.2018.11.040. 9. Panebianco V., Barchetti F., Manenti G., Aversa T., Catalano C., Simonetti G. MR imaging-guided prostate biopsy: technical features and preliminary results. Radiol Med 10. Yaxley A.J., Yaxley J.W., Thangasamy I.A., Ballard E., Pokorny M.R. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging–Reporting and Data System (PI-RADS) 3–5 MRI lesions. BJU Int. 2017 Nov 1;120:43–50, Doi: 10.1111/BJU.13971. 11. Mottet N., van den Bergh R.C.N., Briers E., Van den Broeck T., Cumberbatch M.G., De Santis M., et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Vol. 79, European Urology. Eur Urol; 2021. 243–262. Doi: 10.1016/j.eururo.2020.09.042. 12. Wegelin O., Exterkate L., van der Leest M., Kelder J.C., Bosch J.L.H..R, Barentsz J.O., et al. Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial. Eur Urol Oncol. 2019 Nov;2(6):617–624. Doi: 10.1016/j.euo.2019.08.007. 13. Turkbey B., Rosenkrantz A.B., Haider M.A., Padhani A.R., Villeirs G. Macura K.J., et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 14. Moore C.M., Kasivisvanathan V., Eggener S., Emberton M., Fütterer J.J., Gill I.S,. et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: Recommendations from an international working group. Eur Urol. 2013. Doi: 10.1016/j.eururo.2013.03.030. 15. Stabile A, Dell’Oglio P, Gandaglia G, Fossati N, Brembilla G, Cristel G, et al. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer. Eur Urol Oncol 16. Kaufmann S., Russo G.I,. Bamberg F., Löwe L., Morgia G., Nikolaou K., et al. Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy. World J Urol. 2018;36(5):761–768. Doi: 10.1016/J.EUO.2018.02.002. 17. Oberlin D.T., Casalino D.D., Miller F.H., Matulewicz R.S., Perry K.T., Nadler R.B., et al. Diagnostic Value of Guided Biopsies: Fusion and Cognitive-registration Magnetic Resonance Imaging Versus Conventional Ultrasound Biopsy of the Prostate. Urology 18. Watts K.L., Frechette L., Muller B., Ilinksy D., Kovac E., Sankin A., et al. Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer. Urol Oncol 19. Valerio M., McCartan N., Freeman A., Punwani S., Emberton M., Ahmed H.U. Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer. Urol Oncol 20. Oderda M., Faletti R., Battisti G., Dalmasso E., Falcone M., Marra G., et al. Prostate Cancer Detection Rate with Koelis Fusion Biopsies versus Cognitive Biopsies: A Comparative Study. Urol Int. 2016 Aug 1;97(2):230–237. Doi: 10.1159/000445524. 21. Delongchamps N.B., Peyromaure M., Schull A., Beuvon .F, Bouazza N., Flam T., et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: Comparison of random and targeted biopsies. J Urol. 2013 Feb;189(2):493–499, Doi: 10.1016/J.JURO.2012.08.195. 22. Monda S.M., Vetter J.M., Andriole G.L., Fowler K..J, Shetty A.S., Weese J.R., et al. Cognitive Versus Software Fusion for MRI-targeted Biopsy: Experience Before and After Implementation of Fusion. Urology 23. Klingebiel M., Arsov C., Ullrich T., Quentin M., Al-Monajjed R., Mally D., et al. Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy. Eur J Radiol 24. Xu G., Xiang L., Wu J., Shao H., Liu H., Ding S., et al. The accuracy of prostate lesion localization in cognitive fusion. Clin Hemorheol Microcirc. 2020;74(3):223–229. Doi: 10.3233/CH-180423. 25. Pepe P., Garufi A., Priolo G.D., Pennisi M. Multiparametric MRI/TRUS Fusion Prostate Biopsy: Advantages of a Transperineal Approach. Anticancer Res 26. Loy L.M., Lim G.H., Leow J.J., Lee C.H., Tan T.W., Tan C.H. A systematic review and meta-analysis of magnetic resonance imaging and ultrasound guided fusion biopsy of prostate for cancer detection-Comparing transrectal with transperineal approaches. Urol Oncol
А в т о р д л я с в я з и: В. С. Петов – младший научный сотрудник Института урологии и репродуктивного здоровья человека ФГАОУ ВО «Первый МГМУ им. И. М. Сеченова» Минздрава России (Сеченовский Университет) Москва, Россия; e-mail: pettow@mail.ru